Swiss National Bank Neurocrine Biosciences Inc Transaction History

Swiss National Bank

$150 Billion
Q3 2024

A detailed history of Swiss National Bank transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Swiss National Bank holds 298,700 shares of NBIX stock, worth $37.5 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

298,700

Previous 294,600 1.39%

Holding current value

$37.5 Million

Previous $40.6 Million 15.21%

% of portfolio

0.02%

Previous 0.03%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	BUY	$114.58 - $153.15 $469,778 - $627,915	4,100 Added 1.39%	298,700 $34.4 Million
Q2 2024 Aug 08, 2024	BUY	$130.86 - $143.19 $52,344 - $57,276	400 Added 0.14%	294,600 $40.6 Million
Q1 2024 May 07, 2024	SELL	$130.4 - $143.74 $1.45 Million - $1.6 Million	-11,100 Reduced 3.64%	294,200 $40.6 Million
Q4 2023 Feb 06, 2024	SELL	$106.07 - $132.76 $901,595 - $1.13 Million	-8,500 Reduced 2.71%	305,300 $40.2 Million
Q3 2023 Nov 08, 2023	SELL	$94.02 - $117.1 $3.61 Million - $4.5 Million	-38,400 Reduced 10.9%	313,800 $35.3 Million
Q2 2023 Aug 09, 2023	SELL	$89.53 - $104.87 $2.53 Million - $2.97 Million	-28,300 Reduced 7.44%	352,200 $33.2 Million
Q1 2023 May 10, 2023	SELL	$94.11 - $123.02 $771,702 - $1.01 Million	-8,200 Reduced 2.11%	380,500 $38.5 Million
Q4 2022 Feb 08, 2023	SELL	$106.72 - $127.06 $2.72 Million - $3.24 Million	-25,527 Reduced 6.16%	388,700 $46.4 Million
Q3 2022 Nov 09, 2022	BUY	$92.03 - $107.81 $119,639 - $140,153	1,300 Added 0.31%	414,227 $44 Million
Q2 2022 Aug 09, 2022	BUY	$75.79 - $100.07 $159,159 - $210,147	2,100 Added 0.51%	412,927 $40.3 Million
Q1 2022 May 09, 2022	BUY	$72.45 - $94.81 $3.71 Million - $4.85 Million	51,200 Added 14.24%	410,827 $38.5 Million
Q4 2021 Feb 08, 2022	SELL	$79.65 - $106.22 $1.06 Million - $1.41 Million	-13,300 Reduced 3.57%	359,627 $30.6 Million
Q3 2021 Nov 08, 2021	SELL	$86.18 - $99.03 $870,418 - $1 Million	-10,100 Reduced 2.64%	372,927 $35.8 Million
Q2 2021 Aug 06, 2021	BUY	$89.43 - $102.27 $3.79 Million - $4.33 Million	42,327 Added 12.42%	383,027 $37.3 Million
Q1 2021 May 07, 2021	BUY	$87.57 - $119.4 $534,177 - $728,340	6,100 Added 1.82%	340,700 $33.1 Million
Q4 2020 Feb 05, 2021	SELL	$86.91 - $108.33 $764,808 - $953,304	-8,800 Reduced 2.56%	334,600 $32.1 Million
Q3 2020 Nov 09, 2020	SELL	$96.16 - $135.15 $326,944 - $459,510	-3,400 Reduced 0.98%	343,400 $33 Million
Q2 2020 Aug 05, 2020	BUY	$85.09 - $130.36 $621,157 - $951,628	7,300 Added 2.15%	346,800 $42.3 Million
Q1 2020 May 08, 2020	BUY	$75.11 - $113.76 $4.9 Million - $7.42 Million	65,200 Added 23.77%	339,500 $29.4 Million
Q4 2019 Feb 06, 2020	BUY	$86.8 - $118.57 $8.9 Million - $12.2 Million	102,500 Added 59.66%	274,300 $29.5 Million
Q3 2019 Nov 12, 2019	BUY	$83.82 - $101.5 $243,077 - $294,350	2,900 Added 1.72%	171,800 $15.5 Million
Q2 2019 Aug 02, 2019	BUY	$72.24 - $91.27 $267,288 - $337,699	3,700 Added 2.24%	168,900 $14.3 Million
Q1 2019 May 10, 2019	BUY	$69.31 - $91.53 $291,102 - $384,426	4,200 Added 2.61%	165,200 $14.6 Million
Q4 2018 Feb 13, 2019	BUY	$68.32 - $124.36 $307,439 - $559,620	4,500 Added 2.88%	161,000 $11.5 Million
Q2 2018 Aug 09, 2018	BUY	$75.3 - $105.99 $210,840 - $296,772	2,800 Added 1.82%	156,500 $15.4 Million
Q1 2018 May 04, 2018	BUY	$75.88 - $92.43 $265,580 - $323,505	3,500 Added 2.33%	153,700 $12.7 Million
Q4 2017 Feb 07, 2018	BUY	$58.53 - $77.59 $169,737 - $225,011	2,900 Added 1.97%	150,200 $11.7 Million
Q3 2017 Nov 03, 2017	BUY	$47.97 - $61.28 $7.07 Million - $9.03 Million	147,300	147,300 $9.03 Million

Others Institutions Holding NBIX

# of Institutions

629

Shares Held

94.2M

Call Options Held

692K

Put Options Held

406K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Neurocrine Biosciences Inc Transaction History